Davis R M Inc. Lowers Stake in IDEXX Laboratories, Inc. $IDXX

Davis R M Inc. cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 91,963 shares of the company’s stock after selling 1,520 shares during the quarter. Davis R M Inc.’s holdings in IDEXX Laboratories were worth $51,673,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. SHP Wealth Management acquired a new position in IDEXX Laboratories during the fourth quarter valued at approximately $26,000. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter valued at $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories during the 4th quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares during the period. Finally, Wormser Freres Gestion increased its holdings in IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $545.00 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a market cap of $42.99 billion, a P/E ratio of 40.13, a price-to-earnings-growth ratio of 3.02 and a beta of 1.55. The stock has a 50 day moving average of $555.83 and a 200-day moving average of $596.69.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on IDXX. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup began coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. UBS Group reduced their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.